Authorized purpose: Automatically determine volumetric breast density, breast volume, and an ACR BI-RADS 5th Edition breast-density category from compatible digital mammography and digital breast tomosynthesis data to aid healthcare professionals in assessing breast tissue composition; it is not a diagnostic aid.
Clinical role
Automated quantitative breast-density assessment as an adjunct to professional breast-imaging review; the output supports, but does not replace, the healthcare professional's assessment.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Not a diagnostic aid. Compatibility is acquisition- and image-type-specific: the packet demonstrates density-score compatibility with GE, Siemens, Hologic, and Fujifilm and VBD/BV compatibility with GE, Siemens, and Hologic. Five reader-study exams were excluded for non-compliant DICOM headers, and the FDA-labeled scope is women undergoing digital mammography or DBT rather than an unrestricted population or modality.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automatically determine volumetric breast density, breast volume, and an ACR BI-RADS 5th Edition breast-density category from compatible digital mammography and digital breast tomosynthesis data to aid healthcare professionals in assessing breast tissue composition; it is not a diagnostic aid.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Compatible digital mammography and digital breast tomosynthesis data: FOR PRESENTATION (processed) mammography images and synthetic 2D DBT images, with at least the four standard bilateral MLO and CC views; the intended patient population is women having a digital mammogram or DBT exam.
Who uses it?Intended users: Healthcare professionals involved in breast imaging
What does the software produce?Output: Density Grade using ACR BI-RADS 5th Edition categories A, B, C, or D; volumetric breast density (VBD) as a percentage; and breast volume in cm3.
What is its most important limitation?Key limitation: Not a diagnostic aid. Compatibility is acquisition- and image-type-specific: the packet demonstrates density-score compatibility with GE, Siemens, Hologic, and Fujifilm and VBD/BV compatibility with GE, Siemens, and Hologic. Five reader-study exams were excluded for non-compliant DICOM headers, and the FDA-labeled scope is women undergoing digital mammography or DBT rather than an unrestricted population or modality.
Clinical takeaway. Clinical role: Automatically determine volumetric breast density, breast volume, and an ACR BI-RADS 5th Edition breast-density category from compatible digital mammography and digital breast tomosynthesis data to aid healthcare professionals in assessing breast tissue composition; it is not a diagnostic aid.
Evidence takeaway. Evidence from the reviewed source record: FDA K232096 evaluated 10,804 women aged 40-92, including 10,804 FFDM exams and 833 DBT exams; the test data were independent of training and came from multiple vendors and countries. VBD correlation with a physics-based model was 0.935 (95% CI 0.931-0.938) in 5,468 exams, breast-volume correlation was 0.997, and VBD correlation with same-patient breast MRI was 0.908 (95% CI 0.878-0.931) in 190 exams. CC/MLO VBD correlation was 0.947 with 1.22% mean absolute deviation in 10,804 exams; DM/DBT VBD correlation was 0.912 with 1.68% mean absolute deviation in 433 exams. In a reader comparison of 400 mammography and 400 DBT exams assessed by eight MQSA-qualified radiologists, four-category accuracy was 70.8% (weighted kappa 0.74) and dense/non-dense accuracy was 88.9% (weighted kappa 0.78); dense/non-dense sensitivity was 87.3% (95% CI 83.6%-90.3%) and specificity was 90.4% (95% CI 87.2%-92.9%).
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automatically determine volumetric breast density, breast volume, and an ACR BI-RADS 5th Edition breast-density category from compatible digital mammography and digital breast tomosynthesis data to aid healthcare professionals in assessing breast tissue composition; it is not a diagnostic aid.
Automated quantitative breast-density assessment as an adjunct to professional breast-imaging review; the output supports, but does not replace, the healthcare professional's assessment.
Compatible digital mammography and digital breast tomosynthesis data: FOR PRESENTATION (processed) mammography images and synthetic 2D DBT images, with at least the four standard bilateral MLO and CC views; the intended patient population is women having a digital mammogram or DBT exam.
Breast-imaging screening and diagnostic assessment workflow; the FDA test data came from hospitals, but the packet does not establish a single required facility type
Not a diagnostic aid. Compatibility is acquisition- and image-type-specific: the packet demonstrates density-score compatibility with GE, Siemens, Hologic, and Fujifilm and VBD/BV compatibility with GE, Siemens, and Hologic. Five reader-study exams were excluded for non-compliant DICOM headers, and the FDA-labeled scope is women undergoing digital mammography or DBT rather than an unrestricted population or modality.
FDA K232096 evaluated 10,804 women aged 40-92, including 10,804 FFDM exams and 833 DBT exams; the test data were independent of training and came from multiple vendors and countries. VBD correlation with a physics-based model was 0.935 (95% CI 0.931-0.938) in 5,468 exams, breast-volume correlation was 0.997, and VBD correlation with same-patient breast MRI was 0.908 (95% CI 0.878-0.931) in 190 exams. CC/MLO VBD correlation was 0.947 with 1.22% mean absolute deviation in 10,804 exams; DM/DBT VBD correlation was 0.912 with 1.68% mean absolute deviation in 433 exams. In a reader comparison of 400 mammography and 400 DBT exams assessed by eight MQSA-qualified radiologists, four-category accuracy was 70.8% (weighted kappa 0.74) and dense/non-dense accuracy was 88.9% (weighted kappa 0.78); dense/non-dense sensitivity was 87.3% (95% CI 83.6%-90.3%) and specificity was 90.4% (95% CI 87.2%-92.9%).
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K232096 evaluated 10,804 women aged 40-92, including 10,804 FFDM exams and 833 DBT exams; the test data were independent of training and came from multiple vendors and countries. VBD correlation with a physics-based model was 0.935 (95% CI 0.931-0.938) in 5,468 exams, breast-volume correlation was 0.997, and VBD correlation with same-patient breast MRI was 0.908 (95% CI 0.878-0.931) in 190 exams. CC/MLO VBD correlation was 0.947 with 1.22% mean absolute deviation in 10,804 exams; DM/DBT VBD correlation was 0.912 with 1.68% mean absolute deviation in 433 exams. In a reader comparison of 400 mammography and 400 DBT exams assessed by eight MQSA-qualified radiologists, four-category accuracy was 70.8% (weighted kappa 0.74) and dense/non-dense accuracy was 88.9% (weighted kappa 0.78); dense/non-dense sensitivity was 87.3% (95% CI 83.6%-90.3%) and specificity was 90.4% (95% CI 87.2%-92.9%).
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Transpara Density 1.0.0 regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K232096
Samplen=10804
IndependenceIndependence not established
K232096
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K232096. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Compatible digital mammography and digital breast tomosynthesis data: FOR PRESENTATION (processed) mammography images and synthetic 2D DBT images, with at least the four standard bilateral MLO and CC views; the intended patient population is women having a digital mammogram or DBT exam.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: To operate clinically, the module must be embedded in an application that generates standardized output such as DICOM and communicates with external devices such as PACS. The FDA packet does not establish a specific current PACS, RIS, EHR, interface version, or deployment model.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes Transpara Density as an optional feature of Transpara that, to operate in a clinical environment, must be embedded in a software application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Transpara Density is designed as an optional feature of Transpara. To operate in a clinical environment the software must be embedded in a software application". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Density Grade using ACR BI-RADS 5th Edition categories A, B, C, or D; volumetric breast density (VBD) as a percentage; and breast volume in cm3.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Density Grade using ACR BI-RADS 5th Edition categories A, B, C, or D; volumetric breast density (VBD) as a percentage; and breast volume in cm3.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes Transpara Density as an optional feature of Transpara that, to operate in a clinical environment, must be embedded in a software application. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Transpara Density is designed as an optional feature of Transpara. To operate in a clinical environment the software must be embedded in a software application". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
To operate clinically, the module must be embedded in an application that generates standardized output such as DICOM and communicates with external devices such as PACS. The FDA packet does not establish a specific current PACS, RIS, EHR, interface version, or deployment model.
ScreenPoint Medical's security reporting page states its security program is aligned with ISO/IEC 27001 and describes a vulnerability reporting channel for Transpara. It states alignment, not certification; no controls are listed. Vendor-wide.
Vendor-wide
Checked 2026-10-25
Vendor statement, not an attestation; exact-release scope is not established.
ACR AI Central provides an exact-submission model card for Transpara Density 1.0.0; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K232096 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.